Janssen, Scripps discover small molecule for flu

Janssen and Scripps have generated an oral compound for treating flu that inhibits the HA protein on influenza H1 and H5 strains.

Recent studies have led to the development of broadly neutralizing antibodies (bNAbs) that target the conserved stem of influenza hemagglutinin (HA) as universal flu vaccines or therapeutics. While there are a handful of HA stem bnAbs in the clinic, antibodies are not suited for oral delivery and pose supply chain challenges...